Koselugo (Selumetinib) is the FIRST and ONLY FDA-approved prescription medicine that is used to treat children 2 years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas that cannot be completely removed by surgery. It is not known if Koselugo is safe and effective in children under 2 years of age. And, it is about to be approved in Korea.

The FDS last year supported the drug by designating it as an "Expanded Review target for Expedited Review". According to industries on the 7th, the MFDS recently completed a safety and validity examination of AstraZeneca's Koselugo.

Koselugo is a new drug used in the treatment of type 1 neurofibromatosis, which is inop